Summary & Overview
HCPCS J7321: Hyaluronan Injection for Intra-articular Use
HCPCS Level II code J7321 covers single-dose hyaluronan or derivative products (Hyalgan, Supartz, Visco-3) used for intra-articular injections, commonly for osteoarthritis-related joint symptoms. The code is widely used across outpatient settings where viscosupplementation is performed, and it matters nationally because these products represent a non-systemic therapeutic option with specific billing rules and payer coverage variations that affect access and cost of care.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage patterns, billing benchmarks, and clinical context for intra-articular hyaluronan therapy. The summary highlights common sites of service and service type, relevant coding considerations, and where to expect policy variability among major payers.
This publication provides operational guidance on documentation and claim-line composition (without clinical recommendations), summarizes payer coverage themes and exclusions, and outlines typical billing practice for per-dose administration. Data not available in the input is noted where applicable; the report focuses on national implications for practice managers, revenue cycle staff, and clinicians involved in outpatient joint injection services.
Billing Code Overview
HCPCS Level II code J7321 describes hyaluronan or derivative (Hyalgan, Supartz, or Visco-3) for intra-articular injection, billed per dose. This code represents viscosupplementation products administered directly into a joint space, typically the knee, to provide symptomatic relief of osteoarthritis and improve joint lubrication.
Service Type: Intra-articular therapeutic injection (viscosupplementation)
Typical Site of Service: Outpatient clinic, physician office, or ambulatory surgical center
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old ambulatory adult with symptomatic osteoarthritis of the knee experiencing persistent joint pain and functional limitation despite conservative care (oral NSAIDs, physical therapy, activity modification). The patient presents to an outpatient orthopedic clinic or ambulatory surgical center for an intra-articular viscosupplement injection using a hyaluronan derivative billed as J7321 (Hyalgan, Supartz, or VISCO-3) per dose. The clinical workflow includes pre-procedure assessment of indication and contraindications, informed consent, skin antisepsis, optional local anesthetic, image guidance or palpation-guided joint localization, aseptic intra-articular injection of the hyaluronan product, post-injection observation, and documentation of laterality (use RT or LT modifier as applicable) and lot/supply management (e.g., JW if partial vial wasted). Typical site of service is an outpatient clinic, physician office, or ambulatory surgical center where sterile intra-articular injections are performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
RT | Right side | When the injection is performed on the right knee (or other right joint) |
LT | Left side | When the injection is performed on the left knee (or other left joint) |
JW | Drug or biological discarded/not administered to any patient | When a portion of a single-use drug vial is discarded after administration and reporting of discarded amount is required |
JZ | No drug product available for administration | When zero drug is administered and reporting indicates none provided (rare for J7321) |
50 | Bilateral procedure | When bilateral joint injections are performed in the same session and payer accepts bilateral modifier on drug billing |
62 | Two surgeons | Rarely used — when two surgeons of different specialties are involved in the procedure |
78 | Return to the operating room for a related procedure during the postoperative period | If a related operative intervention is required during the global period (uncommon for injections) |
52 | Reduced services | When the injection procedure is partially reduced or not fully performed |
53 | Discontinued procedure | If the planned injection is started but aborted prior to administration |
23 | Unusual anesthesia | When unusual anesthesia is required for the injection beyond local infiltration |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207X00000X | Orthopaedic Surgery | Orthopedists commonly perform intra-articular viscosupplement injections |
208000000X | Physical Medicine & Rehabilitation | PM&R physicians perform joint injections for osteoarthritis management |
207L00000X | Sports Medicine | Sports medicine specialists often administer viscosupplementation |
3336C0002X | Pain Medicine | Interventional pain physicians may perform therapeutic joint injections |
207Y00000X | Hand Surgery / Related Orthopedics | Some subspecialists provide injections for non-knee joints |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M17.0 | Bilateral primary osteoarthritis of knee | Primary indication for viscosupplementation in patients with symptomatic knee osteoarthritis affecting both knees |
M17.11 | Unilateral primary osteoarthritis, right knee | Common reason to administer an intra-articular hyaluronan injection to the right knee |
M17.12 | Unilateral primary osteoarthritis, left knee | Common reason to administer an intra-articular hyaluronan injection to the left knee |
M17.9 | Osteoarthritis of knee, unspecified | Used when laterality or primary/secondary status is not specified; supports medical necessity for injection |
M17.2 | Bilateral post-traumatic osteoarthritis of knee | Viscosupplementation used for symptomatic degenerative change following prior trauma |
M17.4 | Right knee post-traumatic osteoarthritis | Indicates symptomatic post-traumatic degenerative disease of the right knee suitable for injection |
M25.561 | Pain in right knee | Symptom code that may accompany osteoarthritis and support the medical necessity of intra-articular injection |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
20610 | Arthrocentesis, aspiration and/or injection, major joint or bursa (e.g., shoulder, hip, knee); without ultrasound guidance | Commonly used CPT for injection of hyaluronan into the knee when performed without image guidance |
20611 | Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance, with permanent recording and reporting | Used when ultrasound guidance is performed for needle placement during the intra-articular injection |
99070 | Supplies and materials (e.g., sterile supplies) used for procedures, other than drugs or biologics | Billed by some practices to account for non-pharmaceutical supplies used during the injection encounter |
36000 | Introduction of needle or intracatheter, vein (not directly related to joint injection) | Not typically used for this procedure; included only if IV access or sedation requiring vascular access is provided |
J1050 | Injection, methylprednisolone acetate, 40 mg (example corticosteroid) | May be administered in separate visits for symptom control or diagnostic injection; not billed with J7321 on same joint visit unless clinically distinct |